CD19 and precursor B-cell acute lymphoblastic leukemia: Frameshift code insertion, deletion in CD19 exons 2–5 that encode for the extracellular domain or loss of heterozygosity (LOH) results in epitope loss in 10 to 20% of pediatric B-ALL treated with CD19-directed immunotherapy as detected by clinical flow cytometry [53, 126].